Galera Ther­a­peu­tics to cut 70% of staff in wake of re­jec­tion for ra­dio­ther­a­py com­pli­ca­tion treat­ment

Galera Ther­a­peu­tics is chop­ping 70% of its staff in the wake of a sting­ing FDA re­jec­tion for its ex­per­i­men­tal treat­ment for a ra­dio­ther­a­py com­pli­ca­tion that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER